METTL16 promoted expression of branched-chain amino acid (BCAA), transaminase 1 (BCAT1) and BCAT2 through m6A-dependent manner and reprogramed BCAA metabolism in acute myeloid leukemia.22 In 2022, Ye et al.23 found that METTL16 inhibited ferroptosis to enhance the expression of GPX4, resulting in breast cancer progression. The gene discussed is BCAT2; the disease is acute myeloid leukemia.